

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/122733 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/24 (2006.01)

A61P 37/06 (2006.01)

(21) International Application Number:

PCT/EP2020/086403

(22) International Filing Date:

16 December 2020 (16.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19217665.9 18 December 2019 (18.12.2019) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **FENG, Shu**; c/o Chugai Pharmbody Research Pte Ltd. 3, Biopolis Drive, #07-11 to 16 Synapse, Singapore 138623 (SG). **FISCHER, Jens**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **GAN, Siok Wan**; c/o Chugai Pharmbody Research Pte Ltd. 3, Biopolis Drive, #07-11 to 16 Synapse, Singapore 138623 (SG). **GEORGES, Guy**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **GERTZ, Michael**; c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel (CH). **HO, Wei Shiong Adrian**; c/o Chugai Pharmbody Research Pte Ltd. 3, Biopolis Drive, #07-11 to 16 Synapse, Singapore 138623 (SG). **JOCHNER, Anton**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **JORDAN, Gregor**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **KETTENBERGER, Hubert**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **LAM, Runyi Adeline**; c/o Chugai Pharmbody Research Pte Ltd. 3, Biopolis Drive, #07-11 to 16 Synapse, Singapore 138623 (SG). **MAJETY, Meher**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **MOELLEKEN, Joerg**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg DEUTSCHLAND (DE). **RUNZA, Valeria**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **SCHAEFER, Martin**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **SCHLOTHAUER, Tilman**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **TIEFENTHALER, Georg**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg

(DE). **VIERT, Maria**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE).

(74) Agent: **BURGER, Alexander** et al.; Nonnenwald 2, 82377 Penzberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC ANTI-CCL2 ANTIBODIES

(57) Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

WO 2021/122733 A1